Literature DB >> 12103270

Urocortin promotes hemodynamic and bioenergetic recovery and improves cell survival in the isolated rat heart exposed to ischemia/reperfusion.

Tiziano M Scarabelli1, Evasio Pasini, Anastasis Stephanou, Laura Comini, Salvatore Curello, Riccardo Raddino, Roberto Ferrari, Richard Knight, David S Latchman.   

Abstract

OBJECTIVES: This study evaluates the hemodynamic, bioenergetic and cytoprotective effects of urocortin (Ucn) in the isolated rat heart exposed to ischemia (I)/reperfusion (R).
BACKGROUND: We have previously demonstrated that administration of exogenous Ucn reduces infarct size in ischemic-reperfused rat hearts.
METHODS: Urocortin 10(-8)M was added to the perfusate before I, before I and during R, and during R alone in the isolated pulsed rat heart exposed to 35 min I followed by 60 min R.
RESULTS: Partial to complete recovery of diastolic pressure and developed pressure was seen irrespective of when Ucn was perfused. In particular, beneficial effects are observed when Ucn is only given during R. Urocortin given only before I, and before I and over R, although not during R alone, also produces significant recovery of high-energy phosphate pools. In each group, improvement in ventricular function is associated with reduction both in myocardial damage, assessed by creatine phosphokinase release, and in endothelial cell and cardiomyocyte apoptosis, assessed by caspase 3 activity and fluorescent-based terminal deoxynucleotidyl transferase mediated nick end labelling enhanced with counterstains. These improvements in ventricular performance, bioenergetics and cell survival are not secondary to any inotropic effects of Ucn.
CONCLUSIONS: This is the first report to show enhanced cardiac function induced by Ucn during I/R. Because the cytoprotective and functional benefits are still produced when Ucn is given only at R, these data suggest that Ucn may be useful clinically in the management of myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12103270     DOI: 10.1016/s0735-1097(02)01930-7

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  18 in total

1.  CRF and urocortin 3 protect the heart from hypoxia/reoxygenation-induced apoptosis in zebrafish.

Authors:  Tegan A Williams; Jillian C Bergstrome; Juliana Scott; Nicholas J Bernier
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-05-24       Impact factor: 3.619

2.  Corticotropin-releasing factor-2 activation prevents gentamicin-induced oxidative stress in cells derived from the inner ear.

Authors:  Johnvesly Basappa; Sevin Turcan; Douglas E Vetter
Journal:  J Neurosci Res       Date:  2010-10       Impact factor: 4.164

3.  Corticotropin-releasing factor receptor 2 mediates sex-specific cellular stress responses.

Authors:  Eric Kubat; Shilpi Mahajan; Min Liao; Larry Ackerman; Peter T Ohara; Eileen F Grady; Aditi Bhargava
Journal:  Mol Med       Date:  2013-07-24       Impact factor: 6.354

4.  Bradycardic effects of microinjections of urocortin 3 into the nucleus ambiguus of the rat.

Authors:  Vineet C Chitravanshi; Kazumi Kawabe; Hreday N Sapru
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-09-26       Impact factor: 3.619

Review 5.  Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs.

Authors:  Eva M Fekete; Eric P Zorrilla
Journal:  Front Neuroendocrinol       Date:  2006-11-02       Impact factor: 8.606

6.  Urocortin 3 expression at baseline and during inflammation in the colon: corticotropin releasing factor receptors cross-talk.

Authors:  Shilpi Mahajan; Min Liao; Paris Barkan; Kazuhiro Takahashi; Aditi Bhargava
Journal:  Peptides       Date:  2014-01-22       Impact factor: 3.750

7.  Cardiac expression of urocortin (Ucn) in diseased heart; preliminary results on possible involvement of Ucn in pathophysiology of cardiac diseases.

Authors:  Keiichi Ikeda; Katsuyoshi Tojo; Goro Tokudome; Makoto Ohta; Ken-ichi Sugimoto; Tadashi Tamura; Naoko Tajima; Seibu Mochizuki; Makio Kawakami; Tatsuo Hosoya
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

8.  Clinical perspectives of urocortin and related agents for the treatment of cardiovascular disease.

Authors:  Keiichi Ikeda; Kouki Fujioka; Yoshinobu Manome; Katsuyoshi Tojo
Journal:  Int J Endocrinol       Date:  2012-04-03       Impact factor: 3.257

9.  New targets of urocortin-mediated cardioprotection.

Authors:  Seán P Barry; Kevin M Lawrence; James McCormick; Surinder M Soond; Mike Hubank; Simon Eaton; Ahila Sivarajah; Tiziano M Scarabelli; Richard A Knight; Christoph Thiemermann; David S Latchman; Paul A Townsend; Anastasis Stephanou
Journal:  J Mol Endocrinol       Date:  2010-05-25       Impact factor: 5.098

10.  Urocortin prevents mitochondrial permeability transition in response to reperfusion injury indirectly by reducing oxidative stress.

Authors:  Paul A Townsend; Sean M Davidson; Samantha J Clarke; Igor Khaliulin; Christopher J Carroll; Tiziano M Scarabelli; Richard A Knight; Anastasis Stephanou; David S Latchman; Andrew P Halestrap
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-05-04       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.